Trial Profile
A study to compare different combinations of Mirabegron (25 or 50 mg) and and antimuscarinic in the treatment of patients with overactive bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2016
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 08 Nov 2016 New trial record
- 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society